A Multicenter, Randomized, Controlled Clinical Trial of Jinghua Weikang Capsule for Maintenance Treatment of Reflux Esophagitis

This clinical trial focuses on exploring the effectiveness of Jinghua Weikang capsules as a maintenance treatment for reflux esophagitis. Reflux esophagitis is a condition where stomach acid frequently flows back into the tube connecting the mouth and stomach, causing irritation. Typically, medications like proton pump inhibitors (PPIs) or potassium competitive acid blockers (P-CAB) are used to manage this condition. However, some patients continue to experience symptoms or severe forms of the disease even after long-term use of these medications. This study is important as it seeks to find alternative ways to manage and reduce the recurrence of symptoms, potentially offering a complementary treatment option that could enhance patient care and address unmet needs in managing this condition. In the trial, participants will receive Jinghua Weikang capsules, which are believed to help regulate and relieve symptoms associated with reflux esophagitis. The treatment is administered orally, aiming to provide relief from symptoms such as pain, belching, and acid reflux. Researchers will monitor the participants to evaluate the effectiveness of the capsules in reducing the recurrence of reflux episodes and alleviating symptoms. This study also examines how well Jinghua Weikang capsules work alongside conventional Western medicines, aiming to provide additional benefits without the long-term risks associated with current acid suppression therapies.